Newswise — A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
The study, published today in Nature Communications, shows that Gamma Delta T cells are able to generate immunological memory against previous infections and cancerous targets.
The results challenge the textbook description of Gamma Delta T cells as ‘natural born killers’ with an innate ability to recognise and destroy abnormal cells. Lead author of the study, Professor Ben Willcox from the Institute of Immunology and Immunotherapy at the University of Birmingham, explains the key findings: “Instead of being ‘natural born killers’, we found these cells are actually quite smart. They adapt to and remember what they have encountered in life, which may include infections and pre-cancerous cells.
“This phenomenon of ‘immunological memory’ is what current vaccines exploit, but because Gamma Delta T cells recognise their targets in a different way, they present novel routes to generate vaccines, and also cell therapy approaches against infection and cancer.”
In order to harness these “adaptive” abilities of Gamma Delta T cells, work is now required to identify the mechanism by which they recognise abnormal cells.
“We are working with other partners to understand exactly how these cells recognise signs of abnormality in infection and cancer, focussing on human cohorts. This knowledge will be crucial to help us build on the current study and explore how to develop new cell therapies and vaccines that exploit Gamma Delta T cells,” adds Professor Willcox.ENDSFor more information, contact Liz Bell, Communications Manager for Science and Technology at the University of Birmingham, on +44 (0)121 414 2772.Notes to editors:
Davey et al. (2017) ‘Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance’ Nature Communications DOI: 10.1038/NCOMMS14760
The study was conducted by researchers from the University of Birmingham, Cardiff University and Pirogov Russian National Research Medical University, and was funded by the Wellcome Trust.
MEDIA CONTACTRegister for reporter access to contact details
Nature Communications, March 2017